Acquisition expands scientific informatics for research workflows

Revvity, Inc is set to acquire ACD/Labs, a global leader in scientific software, in a move that strengthens Revvity Signals’ footprint across research, development, and manufacturing workflows. The deal, expected to close in Q4 2025, brings together two innovators in analytical science and molecular design.

ACD/Labs’ portfolio includes tools for spectral analysis (Spectrus®), AI-driven molecular property prediction (Percepta®), high-throughput experimentation (Katalyst D2D®), and enterprise data management (ADMS). Integrating these capabilities into Revvity Signals will allow scientists to bridge the gap between complex data and actionable insights, streamlining workflows from molecule discovery to manufacturing quality control.

“By combining our technologies, we’re creating a unified SaaS environment that connects molecular design, analytical science, and manufacturing oversight,” said Kevin Willoe, President of Revvity Signals Software. “This gives scientists faster, more confident insight across the entire workflow.”

Daria Thorp, President and CEO of ACD/Labs, added: “Joining forces with Revvity Signals unites two leaders in scientific software. Together, we’ll expand the reach of our technology and deliver end-to-end solutions that empower researchers with deeper insight and continuity.”

More information online